Volume 1, Issue 12
Editorialp. 1601
Personalized medicine in non-smallcell lung cancer: has it come of age?
Author(s): Martin Sebastian, Martin Reck
Research Articlep. 1609
Experience in international clinical research: the HIV Prevention Trials Network
Author(s): Nirupama Deshmane Sista, Quarraisha Abdool Karim, Kathy Hinson, Deborah Donnell, Susan H Eshleman,Sten H ermund
Review: Clinical Trail Outcomesp. 1619
Assessing nocturia in clinical trials
Author(s): Svetlana Avulova , Jeffrey P Weiss
Clinical Trail Outcomesp. 1627
Design of clinical trials for biomarker research in oncology
Author(s): Sumithra J Mandrekar, Daniel J Sargent
Patient Perspectivep. 1637
miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma
Author(s): Krishan Jethwa, Jun Wei, Kayla McEnery,Amy B Heimberger
Therapeutic Prospectivep. 1651
Anti-angiogenic therapy for prostate cancer: rationale and ongoing trials
Author(s): Bamidele A Adesunloye, William L Dahut
Research Articlep. 1663
Incentives and barriers to neurological clinical research participation
Author(s): Anne S Lindblad, Pam Zingeser, Nil Sismanyazici-Navaie
Review Articlep. 1669
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Author(s): Eva Baroke, Shyam Maharaj, Martin Kolb
Review Articlep. 1681
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Author(s): Raoul Tibes, Ruben Mesa
Review Articlep. 1695
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Author(s): Brendan Boyce, Lianping Xing
Proceedingsp. 1707
miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma
Author(s): Krishan Jethwa, Jun Wei, Kayla McEnery & Amy B Heimberger
Review Articlep. 1717
Boceprevir in the treatment of hepatitis C infection: rationale and clinical data
Author(s): Omer Khalid ,Bruce R Bacon
